The TCR-T cell therapies of tomorrow

Beyond Biotech - the podcast from Labiotech

Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

2M ago 26:42

MP3•Episode home

Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1.

The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing.

The company has raised more than €100m to date.

On the podcast this week, we have a conversation with Jarvis about TCR-T cell therapies, creating off-the-shelf products and partnerships with EmendoBio and Shinobi Therapeutics.

00:43-02:10: About Anocca
02:10-04:16: About TCR-T cell therapies and their use in treatments
04:16-06:02: Anocca’s approach to T-cell biology, cutting-edge biotechnologies and integrated software
06:02-07:58: A different approach to other cell and gene therapy companies
07:58-09:16: Facing challenges
09:16-10:48: Addressing conditions and diseases
10:48-11:54: Pancreatic cancer
11:54-13:40: What represents success for Anocca?
13:40-14:09: What is VIDAR-1?
14:09-16:08: Partnerships
16:08-18:05: Scaling up and addressing costs
18:05-20:07: How is TCR-T therapy evolving?
20:07-23:11: The impact of artificial intelligence
23:11-25:16: Anocca timeline
25:16-25:57: Closing comments
`
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Chapters

1. The TCR-T cell therapies of tomorrow (00:00:00)

2. About Anocca (00:00:43)

3. About TCR-T cell therapies and their use in treatments (00:02:10)

4. Anocca’s approach to T-cell biology, cutting-edge biotechnologies and integrated software  (00:04:16)

5. A different approach to other cell and gene therapy companies  (00:06:02)

6. Facing challenges  (00:07:58)

7. Addressing conditions and diseases  (00:09:16)

8. Pancreatic cancer  (00:10:48)

9. What represents success for your treatment?  (00:11:54)

10. What is VIDAR-1?  (00:13:40)

11. Partnerships  (00:14:09)

12. Scaling up and addressing costs  (00:16:08)

13. How is TCR-T therapy evolving?  (00:18:05)

14. The impact of artificial intelligence  (00:20:07)

15. Anocca timeline  (00:23:11)

16. Closing comments (00:25:16)

146 episodes

#News #Tech News #Labiotech